10-Year Partnership Between ISN® and Yara International Enhances Ongoing Commitment to Contractor Safety

 The global leader in crop nutrition continues to leverage ISNetworld® solutions to advance contractor compliance and safety practices

(BUSINESS WIRE)--ISN, the global leader in contractor and supplier information management services, celebrates 10 years of partnership with the European division of Yara International (Yara), a leading provider of crop nutrition and sustainable agricultural solutions. After a successful implementation in the Americas, Yara adopted ISNetworld across its European sites in 2015, expanding its use of the contractor management platform, streamlining processes, and improving operational efficiency.

“Over the past decade, ISN has been instrumental to Yara’s contractor management processes in Norway and the Netherlands," said Steinar Bjelland, Procurement Manager at Yara. "Leveraging ISNetworld tools and services such as RAVS 360™ and acknowledgment form tracking, along with ISN’s multilingual support, has helped Yara optimise compliance, improve communication, and effectively align our protocols with industry best practices.”

Headquartered in Oslo, Norway, Yara operates in more than 60 countries. Yara works to advance responsible farming, reduce environmental impact, and help ensure food security through innovative products and digital solutions. Yara initially implemented ISNetworld in the United States, Canada, and Brazil before expanding into Norway and the Netherlands. By leveraging ISNetworld, Yara has standardised its contractor qualification process and strengthened its contractor safety performance across the globe.

Additionally, ISN’s tools and services have supported Yara in maintaining a proactive and responsive approach to compliance, helping ensure its employees and contractors adhere to the same guidelines, while fostering a culture where individuals feel empowered to speak up. Looking ahead, Yara is exploring the implementation of ISN’s CultureSight® survey to further strengthen its commitment to workplace transparency and to continue to improve its safety culture.

“Yara’s dedication to safety, operational excellence, and regulatory adherence has been evident throughout our decade-long partnership,” said David Bibby, Vice President at ISN. “ISN is proud to help Yara continue its sustainable contribution to the global food system and its mission to find innovative environmental and agriculture solutions.”

For more information on ISN’s industry-leading software and services, visit isn.com.

About ISN

ISN is the global leader in contractor and supplier information management, with more than 20 years of experience connecting more than 850 Hiring Clients in capital-intensive industries with 85,000 active contractors and suppliers to promote safety, health, and sustainability in the workplace. ISN’s brands include ISNetworld®, a global online contractor and supplier management platform, Transparency-One®, a responsible sourcing platform built to bring transparency to supply chain management, and Empower®, a worker-level app built to keep workers moving forward.

ISN has 14 offices around the globe which provide award-winning support and training for its customers in more than 85 countries. ISN takes pride in leading worldwide efforts to improve the efficiency and effectiveness of contractor and supplier management systems and in serving as a world-class forum for sharing industry best practices, benchmarking performance, providing data insights among its members, and helping decision makers, including board members, ensure contractor and supplier risk is assessed and monitored. For more information, visit isn.com.

About Yara International

Yara's mission is to responsibly feed the world and protect the planet. Yara pursues a strategy of sustainable value growth through reducing emissions from crop nutrition production and developing low-emission energy solutions. Yara's ambition is focused on growing a nature-positive food future that creates value for its customers, shareholders, and society at large, and delivers a more sustainable food value chain.

To drive the green shift in fertiliser production, shipping, and other energy intensive industries, Yara will produce ammonia with lower emissions. Yara provides digital tools for precision farming and works closely with partners at all levels of the food value chain to share knowledge and promote more efficient and sustainable solutions. Founded in 1905 to solve the emerging famine in Europe, Yara has established a unique position as the industry's only global crop nutrition company. With 17,000 employees and operations in more than 60 countries, sustainability is an integral part of Yara’s business model. For more information, visit yara.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250514723932/en/

Permalink

https://www.aetoswire.com/en/news/1405202546584

Contacts

Media Contact

Taylor D’Eliseo

Walker Sands for ISN isnpr@walkersands.com

 

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease>

(BUSINESS WIRE)--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause of disability and death. AD develops over many years, long before symptoms are evident, but the lack of accessible, minimally invasive diagnostics results in many patients remaining undiagnosed until the disease is well advanced, when few effective interventions remain. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test is an accurate, minimally invasive, accessible measurement of pTau 217 and β-Amyloid...(BUSINESS WIRE)--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause of disability and death. AD develops over many years, long before symptoms are evident, but the lack of accessible, minimally invasive diagnostics results in many patients remaining undiagnosed until the disease is well advanced, when few effective interventions remain. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test is an accurate, minimally invasive, accessible measurement of pTau 217 and β-Amyloid...{}

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease>

(BUSINESS WIRE)--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause of disability and death. AD develops over many years, long before symptoms are evident, but the lack of accessible, minimally invasive diagnostics results in many patients remaining undiagnosed until the disease is well advanced, when few effective interventions remain. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test is an accurate, minimally invasive, accessible measurement of pTau 217 and β-Amyloid...(BUSINESS WIRE)--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause of disability and death. AD develops over many years, long before symptoms are evident, but the lack of accessible, minimally invasive diagnostics results in many patients remaining undiagnosed until the disease is well advanced, when few effective interventions remain. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test is an accurate, minimally invasive, accessible measurement of pTau 217 and β-Amyloid...{}

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

 OSAKA, Japan & CAMBRIDGE, Mass. - Thursday, 15. May 2025 AETOSWire Print 

–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated

–Oveporexton Found to be Generally Safe and Well Tolerated

–Phase 3 Readout of Oveporexton Anticipated in 2025

 

(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment.

NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis. These debilitating symptoms can markedly reduce an individual’s quality of life and severely impact job performance, academic achievement and personal relationships. Current standard of care includes polypharmacy to manage different symptoms, but none of these medicines target the underlying orexin deficiency that causes NT1.

“Narcolepsy type 1 is a 24-hour disease making it very challenging to function and lead a healthy, productive life,” said principal investigator Yves Dauvilliers, M.D., Director, Sleep-Wake Disorders Center, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France. “Oveporexton is the leading investigational orexin receptor 2 agonist designed to address the underlying pathophysiology of NT1. The supporting data from Takeda’s Phase 2b trial demonstrated clinically meaningful improvements across the full spectrum of symptoms impacting people with NT1.”

“For people living with narcolepsy type 1, going to work or attending school and managing everyday activities like driving, exercising or socializing with family and friends can become daunting challenges,” said Sarah Sheikh, M.D., M.Sc., B.M., B.Ch., MRCP, Head of the Neuroscience Therapeutic Area Unit and Global Development at Takeda. “Our Phase 2b results suggest that restoring orexin signaling has the potential to help people with narcolepsy type 1 achieve near normal ranges of wakefulness as seen in healthy individuals while also positively impacting the broader spectrum of the disease. We are working diligently to further investigate oveporexton and its potential to become the first-in-class, transformative therapeutic option for people living with NT1.”

TAK-861-2001 Phase 2b Trial in NT1

The TAK-861-2001 Phase 2b trial enrolled 112 adults aged 18−70 with NT1 globally. Participants were randomized equally to one of four dosing arms (twice-daily 0.5/0.5 mg, 2/2 mg, 2/5 mg or once-daily 7 mg) or placebo for 8 weeks. The primary and secondary endpoints from the study assessed the impact of oveporexton across subjective and objective measures of wakefulness and daytime sleepiness, cataplexy rates and safety compared to placebo.

Results from the Phase 2b trial showed:

The primary endpoint demonstrated substantial increases in mean sleep latency on the Maintenance of Wakefulness Test (MWT), a key measure of wakefulness, with improvements across all doses compared to placebo (adjusted p ≤0.001 for all comparisons) sustained over 8 weeks. The mean sleep latency on the MWT reached values consistent with normative values seen in healthy individuals.

Key secondary endpoints demonstrated significant reductions in Epworth Sleepiness Scale (ESS) scores, a measure of EDS, and reductions in Weekly Cataplexy Rate (WCR) across all doses compared to placebo and were sustained over 8 weeks.

The Narcolepsy Severity Scale for Clinical Trials (NSS-CT), a self-assessment scale used to assess the severity, frequency and impact across narcolepsy symptoms, and the 36-item short-form (SF-36), used to assess quality of life, were evaluated as exploratory endpoints. NSS-CT domain scores indicated marked improvements across most domains (EDS, cataplexy, hypnagogic hallucinations and sleep paralysis) while clinically meaningful improvements in quality of life as assessed with the SF-36 questionnaire were observed with all oveporexton dose groups compared to placebo.

The most commonly reported treatment-emergent adverse events (TEAEs) were insomnia (43%), increased urinary urgency (30%) and frequency (29%). Most TEAEs were mild to moderate in intensity, and most started within 1-2 days of treatment and were transient. No cases of hepatotoxicity or visual disturbances were reported.

The majority of participants (95%) who completed the trial enrolled in the long-term extension (LTE) study, with many patients reaching one year or more of treatment.

Takeda is leading the field of orexin science with a multi-asset franchise. Oveporexton, the lead program in the franchise, is the first and only orexin agonist in Phase 3 trials. Takeda anticipates a data readout from the Phase 3 trials in calendar year 2025.

About Takeda’s Orexin Agonists for Sleep Wake-Disorders

Takeda is pioneering the field of orexin science with a multi-asset franchise offering tailored treatments. Orexin is a key regulator of the sleep-wake cycle and is involved in other essential functions, including respiration and metabolism. Oveporexton (TAK-861) is the leading investigational asset in this franchise and received Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in narcolepsy type 1 from the U.S. Food and Drug Administration (FDA) and Center for Drug Evaluation of China’s National Medical Products Administration. The company is also progressing orexin agonists in patient populations with normal levels of orexin neuropeptides and other indications where orexin biology is implicated. This includes TAK-360, an oral OX2R agonist being investigated for narcolepsy type 2 and idiopathic hypersomnia, which received Fast Track designation from the FDA.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at https://www.sec.gov/. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508841747/en/

Permalink

https://www.aetoswire.com/en/news/1505202546620

Contacts

Media Contacts:

Japanese Media

Yuko Yoneyama

yuko.yoneyama@takeda.com

U.S. and International Media

Rachel Wallace

rachel.wallace2@takeda.com

Horizon3.ai Gains FedRAMP High Authorization, Delivering on Its Commitment to Secure the Public Sector

 (BUSINESS WIRE) -- Horizon3.ai, the global leader in offensive security, today announced it has gained Federal Risk and Authorization Management Program (FedRAMP®) High Authorization, unlocking the ability to support even the most security-sensitive federal missions. This milestone fulfills Horizon3.ai’s previously announced commitment to bring proof-based security to government agencies operating at the highest levels of compliance and risk exposure.

Horizon3.ai’s newly authorized platform, NodeZero Federal™, is now available to federal agencies under the FedRAMP High baseline. Built upon the proven commercial version of the NodeZero® Offensive Security Platform, NodeZero Federal™ is designed specifically to meet the heightened security and compliance demands of government environments. With this authorization in place, Horizon3.ai becomes the first and only cybersecurity vendor authorized to deliver continuous, autonomous pentesting within this strict regulatory framework.

“We built NodeZero to help defenders find and fix vulnerabilities before attackers exploit them—and with the FedRAMP High authorization, we’re now able to proactively secure critical federal systems,” said Snehal Antani, CEO and Co-founder of Horizon3.ai. “Our roots are in National Security, and with cyber warfare evolving at an unprecedented pace, we’re committed to improving the cyber resilience of the nation’s digital infrastructure, with support for Secret and Top Secret systems as our next major focus areas.”

This authorization builds on Horizon3.ai’s success with Federal partners, such as the NSA Cybersecurity Collaboration Center (CCC) program. As part of CCC, Horizon3.ai powers the NSA’s Continuous Autonomous Penetration Testing (CAPT) program, where Defense Industrial Base (DIB) suppliers use NodeZero to act as nation-state-level adversaries, identify and prioritize real attack paths, and continuously validate their defenses.

“With our FedRAMP High authorization, critical suppliers and federal agencies can verify and improve their cybersecurity posture, ensuring that limited resources are focused on fixing problems that truly matter," said Matt Hartley, CRO at Horizon3.ai. "These agencies can find, fix, and verify the remediation of CISA Known Exploitable Vulnerabilities (KEV) at scale, ensure their security operations center is effectively detecting and stifling attacks, and that security tools are tuned correctly. Offense drives defense, and no one knows this better than our US Federal customers.”

NodeZero Federal helps agencies streamline compliance with key cybersecurity mandates, including NIST SP 800-53—the foundational control framework behind FedRAMP—as well as evolving OMB policies and Executive Orders that require Zero Trust architecture, Cybersecurity Maturity Model Certification (CMMC) 2.0 for supply chain assurance, and participation in Continuous Diagnostics and Mitigation (CDM) programs.

For more information about Horizon3.ai’s NodeZero Federal™ and its FedRAMP High capabilities, visit their website.

About Horizon3.ai

The NodeZero® Offensive Security Platform by Horizon3.ai drives continuous exposure management across production infrastructure. With NodeZero, customers overcome barriers of limited security talent and infrequent, expensive penetration testing. They stay ahead of a rapidly-evolving threat landscape with autonomous pentesting, emerging threat intelligence, threat detection, and unified data and reporting. Founded in 2019 by former industry leaders and U.S. National Security veterans, Horizon3.ai solves diverse use cases across all industries.

Follow Horizon3.ai on LinkedIn and X.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250515365494/en/

Permalink

https://www.aetoswire.com/en/news/1505202546646

Contacts

Media:

Ed Kraft

SourceCode Communications

horizon3@sourcecodecomms.com

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience

 SAN FRANCISCO

Study is the first demonstration of senescent neurons driving neuropathic pain1

Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2

(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nature Neuroscience, a prestigious, peer-reviewed scientific journal, and will be featured on the cover of the May issue.

Dr. Quarta said, “We know that senescent cells, which increase as people age, drive chronic degenerative diseases and conditions. In this study, we were able to show for the first time that neurons can become senescent, fueling neuropathic pain in both mouse models and human dorsal root ganglia tissue. The bioinformatic validation provided as part of our broader ALEMBIC™ platform with SenTeCh™ chemistry technology helped to uncover this link between aging and neuropathic pain, and further corroborates our experimental observations that treatments targeting these senescent cells could offer meaningful benefits for people experiencing age-related conditions.”1

About the Study

In the study, researchers found that injury to peripheral axons of dorsal root ganglion (DRG) neurons results in sensory dysfunction, such as pain. This occurs at higher rates in aged individuals. Furthermore, cellular senescence is common to both aging and injury, and contributes to this sensory dysfunction. Elimination of senescent cells results in pain improvement, indicating a potential target for new pain therapeutics.1

“Chronic pain continues to be an area with high unmet need, especially among older adults. In this study, aging markedly increased the burden of senescent or 'zombie' neurons, which in turn worsened neuropathic pain severity. These insights demonstrate that selective targeting of senescent-like neurons may lead to novel strategies for the management of chronic pain,”1 said Vivianne, L. Tawfik, MD, PhD, Associate Professor, Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine, and the senior author of the study. “We appreciate the valuable support and expertise from the Rubedo team during this research.”

About Rubedo Life Sciences

Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – is set to begin Phase I clinical trials in Spring of 2025, marking the first ever GPX4 modulator to enter a human clinical trial. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.

References

1. Donovan, L.J., Brewer, C.L., Bond, S.F. et al. Aging and injury drive neuronal senescence in the dorsal root ganglia. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-01954-x

2. Data on file, Rubedo Life Sciences, Sunnyvale, CA 94085.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250514558243/en/

Permalink

https://www.aetoswire.com/en/news/1505202546622

Contacts

Investor Contact:

Rubedo Chief Business Officer Ali Siam

alisiam@rubedolife.com

781-974-9559

Media Contact:

Peter Collins

p.collins@togorun.com

908-499-1200

ITEN and A*STAR IME Announce Breakthrough in Solid-State Battery Integration for Advanced Packaging

 (BUSINESS WIRE)--ITEN, a global leader in micro solid-state batteries, and A*STAR Institute of Microelectronics (A*STAR IME), a leader in advanced packaging research, have announced a groundbreaking achievement for the integration of ITEN’s micro batteries using A*STAR IME’s cutting-edge advanced packaging platform. This milestone paves the way for in-package energy storage solutions, enabling more efficient, compact, and reliable system-in-package (SiP) designs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515958544/en/

Revolutionizing Energy Storage and Advanced Packaging

This breakthrough innovation represents a significant leap forward in SiP technology. By embedding ITEN’s high-performance solid-state batteries at the wafer level, ITEN and A*STAR IME have successfully demonstrated integrating non-volatile energy storage directly using advanced packaging. This enables seamless integration, elevating energy efficiency and operational reliability of electronic components.

Key Benefits and Applications

• Enhanced Efficiency: Seamless integration maximizes energy transfer while minimizing power loss, resulting in improved overall performance.
• Compact Design: Embedding micro batteries within the packaging significantly reduces the device footprint, ideal for next-generation portable and wearable devices.
• Increased Reliability: The integration in a single package not only reduces assembly complexity but also improves interconnect reliability. With fewer solder joints and connectors, the potential points of failure decline, which can lead to higher reliability.

A Step Towards a Sustainable Future

The collaboration underscores a shared commitment to environmental sustainability. ITEN’s batteries are free from hazardous materials, providing a safer, eco-friendly alternative. By enabling longer device life and reducing the need for external power components, this innovation contributes to minimizing electronic waste.

Industry Collaboration and Future Prospects

This achievement marks the beginning of a new era in packaging innovation, especially for 3D chip integration architectures with built-in energy sources. ITEN and A*STAR IME are actively exploring future applications in consumer electronics, medical devices, and IoT solutions, where compactness and energy efficiency are critical.

“We are pleased to collaborate with ITEN to develop breakthrough advanced packaging technologies that meet the needs of the growing microelectronics market. Such efforts will enable new applications of SiP, creating new market opportunities,” said Terence Gan, Executive Director of A*STAR IME.

Vincent Cobee, CEO of ITEN, added, “A*STAR IME’s strong knowledge and expertise in advanced packaging technologies support us in accelerating the development of new micro batteries optimized for integration into SiP. This is a major step forward in addressing the challenges of energy efficiency across a wide spectrum of applications.”

Leader in Advanced Packaging Research

A*STAR IME’s research is centered around three architecture families: high density fan-out wafer-level packaging (HD FOWLP), 2.5D interposer and 3D interposer, from which eight platforms are derived: mold-first FOWLP, redistribution layer (RDL)-first FOWLP, passive interposer, active interposer, photonic interposer, wafer-to-wafer (W2W) hybrid bond, chip-to-wafer (C2W) hybrid bond, and C2W micro-bump. A*STAR IME also develops manufacturing techniques, packaging architectures, electrical-thermal-mechanical (ETM) models, and package process design kits (PDK) advancing the industry’s packaging roadmap.

--- ---

About ITEN

ITEN is a global leader in solid-state batteries, pioneering high-power, miniaturized energy storage solutions. With over 200 patents and deep expertise in solid-state technology, ITEN is one of the very few companies worldwide with full industrial production capabilities. The company serves industries requiring compact, high-performance energy storage, including IoT, smart sensors, and wearables. Based in Dardilly, France, ITEN is a two-time winner of the Global Innovation Competition and a French Tech 120 laureate, as well as a recipient of the CES 2024 Best of Innovation Award. By the end of 2022, ITEN had secured €80 million in funding.
www.iten.com

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR’s R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Follow us on
Facebook | LinkedIn | Instagram | YouTube | TikTok

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250515958544/en/

Permalink
https://aetoswire.com/en/news/1505202546635

Contacts

Media
Corinne Cosma corinne.cosma@iten.com
Neo Jie Xin, Manager neo_jie_xin@hq.a-star.edu.sg

Allianz Reports Record Operating Profit and Is Fully on Track to Achieve Full-Year Outlook

 MUNICH -

(BUSINESS WIRE)--May 15, 2025

1Q 2025

Total business volume advances 11.71 percent to 54.0 billion euros reflecting sustained momentum across all segments

Operating profit increases 6.3 percent to 4.2 billion euros, reaching 26 percent of our full-year outlook midpoint

Shareholders’ core net income is stable at a very good level of 2.6 billion euros. Adjusted for a one-off tax provision related to the forthcoming sale of our stake in our Indian Joint Ventures, shareholders’ core net income is up 5 percent

Core earnings per share grow 2.9 percent and reach 6.61 euros. Adjusted for the above-mentioned one-off tax provision, core earnings per share are up 7 percent

Annualized core RoE is robust at 16.6 percent, or 17.2 percent adjusted for the effect of the one-off tax provision

Solvency II capitalization ratio remains strong at 208 percent2

Outlook

Allianz is fully on track to achieve full-year operating profit outlook of 16.0 billion euros, plus or minus 1 billion euros3

A strong balance sheet, limited Solvency II sensitivities, and attractive customer propositions give Allianz a competitive advantage in successfully managing current capital market volatility and geopolitical uncertainty

Other

Share buy-back program of up to 2 billion euros announced on February 27 underway; 0.1 billion euros completed in 1Q 2025

____________________

1

Internal growth; total growth 11.6 percent.

2

Based on quarterly dividend accrual; additional accrual to reflect FY dividend would impact Solvency II capitalization ratio by -10%-p as of March 31, 2025. This applies to all information regarding the Solvency II capitalization ratio in this document.

3

As always, natural catastrophes and adverse developments in the capital markets, as well as factors stated in our cautionary note regarding forward-looking statements may severely affect the operating profit and/or net income of our operations and the results of the Allianz Group.

“Allianz’s first quarter performance and our confirmed outlook underscore our financial strength and resilient business model, which benefits from the attractiveness of our customer value propositions amid geopolitical and economic uncertainty.

In fact, we view this uncertainty and change as a catalyst for innovation and growth, allowing us to pursue new opportunities and expand our offerings. As the world's leading insurance brand, we are well-positioned to benefit from the global flight to trust, with the ability to meet growing customer demand for protection and retirement solutions.”

- Oliver Bäte, Chief Executive Officer of Allianz SE

FINANCIAL HIGHLIGHTS

Allianz Group: Sustained strong momentum and record operating profit

Key performance indicator

 

1Q 2025

 

Change vs

prior year

Total business volume (€ bn)

 

54.0

 

11.7%4

Operating profit (€ mn)

 

4,238

 

6.3%

Shareholders’ core net income (€ mn)

 

2,550

 

1.5%

Core return on equity (annualized) (%)

 

16.6

 

(0.2)%-p5

Solvency II ratio (%)

 

208

 

(1)%-p5

“Allianz had a very good start to the year. We sustained our growth momentum while safeguarding attractive margins across our businesses, evidenced by our record operating profit.

The proven resilience of our business model positions us very well to successfully manage volatile markets and a more uncertain environment. We confidently affirm our full-year operating profit outlook. We are firmly focused on executing the strategic priorities outlined at our Capital Markets Day to deliver on our ambitions.”

- Claire-Marie Coste-Lepoutre, Chief Financial Officer of Allianz SE

In 1Q 2025, Allianz has delivered a very good performance underpinned by sustained momentum across our businesses. The operating profit has reached a record level of 4.2 billion euros (1Q 2024: 4.0 billion euros), an increase of 6.3 percent, supported by growth across all segments.

Our total business volume expanded by 11.71 percent, growing to 54.0 (48.4) billion euros. The Life/Health segment was the main driver, but all business segments contributed.

Shareholders’ core net income was stable at 2.6 billion euros as higher operating profit was compensated by a lower non-operating result and higher taxes. The latter were impacted by a one-off tax provision related to the forthcoming sale of our stake in our Indian Joint Ventures. Adjusted for this provision, shareholders’ core net income was up 5 percent.

Core earnings per share (EPS)6 for 1Q 2025 amounted to 6.61 (6.42) euros, an increase of 2.9 percent. Adjusted for the one-off tax provision, core earnings per share were up 7 percent.

Allianz has generated a robust annualized core return on equity (RoE)6 of 16.6 percent in 1Q 2025 (full-year 2024: 16.9 percent), or 17.2 percent adjusted for the above-mentioned one-off tax provision.

This performance was achieved while we maintained our financial strength with a stable Solvency II ratio of 208 percent (full-year 2024: 209 percent).

____________________

4

Change refers to internal growth.

5

Change versus December 31, 2024.

6

Core EPS and core RoE calculation based on shareholders‘ core net income.

Outlook

Allianz is fully on track to achieve its full-year outlook of an operating profit of 16.0 billion euros, plus or minus 1 billion euros.

A strong balance sheet, limited Solvency II sensitivities, and attractive product propositions position Allianz very well to manage volatile markets and geopolitical uncertainty.

Other

The share buy-back program of up to 2 billion euros, announced on February 27, 2025, is underway and 0.1 billion euros were completed during 1Q 2025.

Property-Casualty insurance: Sustained growth momentum and excellent profitability

Key performance indicator

 

1Q 2025

 

Change vs

prior year

Total business volume (€ bn)

 

27.0

 

7.1%7

Operating profit (€ mn)

 

2,170

 

5.0%

Combined ratio (%)

 

91.8

 

(0.1)%-p

Loss ratio (%)

 

67.7

 

0.4%-p

Expense ratio (%)

 

24.1

 

(0.5)%-p

Core messages Property-Casualty insurance 1Q 2025

Strong segment performance with very good internal growth and record operating profit

Broad-based internal growth, in particular in retail8

Operating profit reaches 27 percent of our full-year outlook midpoint

Combined ratio excellent, reflecting successful underwriting actions and productivity gains

In 1Q 2025, total business volume reached 27.0 (1Q 2024: 25.5) billion euros. The very good internal growth of 7.1 percent continued to be underpinned by healthy rate increases, in particular in retail8. Commercial9 momentum remained resilient but slowed down. Allianz maintained a successful balance of growing its business while maintaining underwriting discipline.

The operating profit of 2.2 (2.1) billion euros, the highest quarterly operating profit ever, marks a successful start to the year, reaching 27 percent of our full-year outlook midpoint. Operating profit advanced 5 percent compared to last year, driven by a higher insurance service result.

The combined ratio improved slightly to an excellent level of to 91.8 percent (91.9 percent) exceeding our full-year outlook of ~93 percent. The loss ratio was 67.7 percent (67.3 percent). Natural catastrophe claims increased compared to a benign first quarter last year, but these were partly offset by a better run-off result.

The expense ratio developed favorably by 0.5 percentage points to 24.1 percent.

The retail8 business showed an excellent performance. It delivered strong internal growth of 9 percent while further improving its combined ratio to 91.8 percent (93.0 percent).

In the commercial9 business, internal growth of 5 percent was good, reflecting the sustained momentum of the business, while navigating a slowing pricing environment. The segment achieved a strong combined ratio of 91.7 percent (89.9 percent).

____________________

7

Change refers to internal growth.

8

Retail including SME and Fleet.

9

Commercial including large Corporate, MidCorp, credit insurance, internal and 3rd party R/I.

Life/Health insurance: Excellent new business growth

Key performance indicator

 

1Q 2025

 

Change vs

prior year

PVNBP (€ mn)

 

26,095

 

16.8%

New business margin (%)

 

5.5

 

(0.2)%-p

VNB (€ mn)

 

1,440

 

13.6%

Operating profit (€ mn)

 

1,427

 

7.5%

Contractual Service Margin (€ bn, eop)10

 

57.0

 

1.9%11

Core messages Life/Health insurance 1Q 2025

Excellent broad-based new business momentum at attractive margin

Strong growth in value of new business, spread across all major operating entities

91 percent of new business premiums generated in preferred lines of business

Operating profit strong at 1.4 billion euros, reaching 26 percent of our full-year outlook midpoint

In 1Q 2025, PVNBP, the present value of new business premiums, grew by 16.8 percent to 26.1 (1Q 2024: 22.3) billion euros. This excellent growth was broad-based, reflecting the strength of our global franchise and attractiveness of our customer value proposition. 91 percent of our new business premiums were generated in our preferred lines of business.

The new business margin (NBM) was at an attractive level of 5.5 percent (5.7 percent) and the value of new business (VNB) increased strongly by 13.6 percent to 1.4 (1.3) billion euros.

Operating profit rose to 1.4 (1.3) billion euros, an increase of 7.5 percent. This strong performance was supported by growth in most regions.

Contractual Service Margin (CSM) advanced from 55.6 billion euros at the end of 2024 to 57.0 billion euros.10 Normalized CSM growth in the first quarter was excellent at 1.9 percent, ahead of our full-year guidance of ~5 percent normalized annual growth.

____________________

10

Includes gross CSM of 0.8 billion euros (as of December 31, 2024, and as of March 31, 2025), for UniCredit Allianz Vita S.p.A., which was classified as held for sale in the third quarter of 2024. In the first quarter of 2025, the German APR and the Austrian health businesses were transferred from the Property-Casualty segment to the Life/Health segment resulting in a 1.2 billion euro shift in the gross CSM opening balance.

11

Normalized CSM growth as of March 31, 2025.

Asset Management: Strong operating profit and third-party net inflows

Key performance indicator

 

1Q 2025

 

Change vs

prior year

Operating revenues (€ bn)

 

2.1

 

2.7%12

Operating profit (€ mn)

 

811

 

4.8%

Cost-income ratio (%)

 

61.3

 

0.1%-p

Third-party net flows (€ bn)

 

28.7

 

(16.2)%

Third-party assets under management (€ bn)

 

1,914

 

(0.3)%13

Core messages Asset Management 1Q 2025

Operating profit advances 5 percent to 811 million euros, on track for full-year outlook

Strong third-party net inflows of 28.7 billion euros. PIMCO and Allianz Global Investors contribute

Assets under management (AUM)-driven revenues grow 10 percent

In 1Q 2025, operating revenues increased to 2.1 billion euros, an internal growth of 2.7 percent. This was fueled by higher AuM-driven revenues, which increased by 10 percent.

Operating profit rose to a strong level of 811 (1Q 2024: 773) million euros, up 4.8 percent. Adjusted for foreign currency translation effects, operating profit increased by 2.5 percent. The cost-income ratio (CIR) was broadly stable at 61.3 percent (61.1 percent), reflecting ongoing productivity management.

Third-party assets under management were largely unchanged compared to year-end 2024 and amounted to 1.914 trillion euros as of March 31, 2025. Strong net inflows of 28.7 billion euros and positive market effects were offset by foreign currency translation effects.

____________________

12

Internal growth.

13

Compared to December 31, 2024.

1Q 2025 RESULTS TABLE

Allianz Group - key figures 1Q 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1Q 2025

 

1Q 2024

 

Delta

 

 

Total business volume

 

 

€ bn

 

54.0

 

48.4

 

11.6%

 

 

- Property-Casualty

 

 

 

€ bn

 

27.0

 

25.5

 

6.0%

 

 

- Life/Health

 

 

 

€ bn

 

25.0

 

21.1

 

18.6%

 

 

- Asset Management

 

 

 

€ bn

 

2.1

 

2.0

 

5.1%

 

 

- Consolidation

 

 

€ bn

 

(0.1)

 

(0.2)

 

(36.5)%

 

 

Operating profit / loss

 

 

 

€ mn

 

4,238

 

3,986

 

6.3%

 

 

- Property-Casualty

 

 

 

€ mn

 

2,170

 

2,066

 

5.0%

 

 

- Life/Health

 

 

 

€ mn

 

1,427

 

1,327

 

7.5%

 

 

- Asset Management

 

 

 

€ mn

 

811

 

773

 

4.8%

 

 

- Corporate and Other

 

 

 

€ mn

 

(165)

 

(179)

 

(7.6)%

 

 

- Consolidation

 

 

 

€ mn

 

(4)

 

(2)

 

85.4%

 

 

Net income

 

 

 

€ mn

 

2,581

 

2,631

 

(1.9)%

 

 

- attributable to non-controlling interests

 

€ mn

 

158

 

156

 

1.4%

 

 

- attributable to shareholders

 

 

€ mn

 

2,423

 

2,475

 

(2.1)%

 

 

Shareholders’ core net income1

 

€ mn

 

2,550

 

2,513

 

1.5%

 

 

Core earnings per share2

 

€

 

6.61

 

6.42

 

2.9%

 

 

Additional KPIs

 

 

 

 

 

 

 

 

 

 

 

- Group

 

Core return on equity3

 

%

 

16.6%

 

16.9%

 

(0.2)%

-p

 

- Property-Casualty

 

Combined ratio

 

%

 

91.8%

 

91.9%

 

(0.1)%

-p

 

- Life/Health

 

New business margin

 

%

 

5.5%

 

5.7%

 

(0.2)%

-p

 

- Asset Management

 

Cost-income ratio

 

%

 

61.3%

 

61.1%

 

0.1%

-p

 

 

 

 

 

 

 

03/31/2025

 

12/31/2024

 

Delta

 

 

Shareholders' equity4

 

 

 

€ bn

 

62.4

 

60.3

 

3.5%

 

 

Contractual service margin (net)5

 

€ bn

 

34.8

 

34.5

 

0.6%

 

 

Solvency II capitalization ratio6

 

%

 

208%

 

209%

 

(1)%

-p

 

Third-party assets under management

 

 

 

€ bn

 

1,914

 

1,920

 

(0.3)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Please note: The figures are presented in millions of Euros, unless otherwise stated. Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

1_

Presents the portion of shareholders’ net income before non-operating market movements and before amortization of intangible assets from business combinations (including any related income tax effects).

2_

Calculated by dividing the respective period’s shareholders' core net income, adjusted for net financial charges related to undated subordinated bonds classified as shareholders' equity, by the weighted average number of shares outstanding (basic core EPS).

3_

Represents the annualized ratio of shareholders’ core net income to the average shareholders’ equity at the beginning and at the end of the period. Shareholders’ core net income is adjusted for net financial charges related to undated subordinated bonds classified as shareholders’ equity. From the average shareholders’ equity, undated subordinated bonds classified as shareholders’ equity, unrealized gains and losses from insurance contracts and other unrealized gains and losses are excluded. Annualized figures are not a forecast for full year numbers. For 1Q 2024, the core return on equity for the respective full year is shown.

4_

Excluding non-controlling interests.

5_

Includes net CSM of EUR 0.2bn (31.12.24: EUR 0.3bn) as of 31 March 2025, for UniCredit Allianz Vita S.p.A., which was classified as held for sale in the 3Q 2024.

6_

Risk capital figures are group diversified at 99.5% confidence level. Solvency II capitalization ratio is based on quarterly dividend accrual; additional accrual to reflect FY dividend would impact solvency II capitalization ratio by -10%-p as of 31 March 2025.

RATING

Ratings

 

S&P

 

Moody’s

 

A.M. Best1

Insurer financial strength rating

 

AA | stable outlook

 

Aa2 | stable outlook

 

A+ | stable outlook

Counterparty credit rating

 

AA | stable outlook

 

not rated

 

Aa | stable

Senior unsecured debt rating

 

AA

 

Aa2 | stable outlook

 

Aa | stable

Subordinated debt rating2

 

A+/A

 

A1/A3 | stable outlook

 

aa- / a+ | stable

Commercial paper (short term) rating

 

A-1+

 

Prime-1

 

Not rated

____________________

1

A.M. Best's Rating Reports reproduced on www.allianz.com appear under licence from A.M. Best Company and do not constitute, either expressly or implicitly, an endorsement of Allianz's products or services. A.M. Best's Rating Reports are the copyright of A.M. Best Company and may not be reproduced or distributed without the express written consent of A.M. Best Company. Visitors to www.allianz.com are authorised to print a single copy of the rating report displayed there for their own use. Any other printing, copying or distribution is strictly prohibited. A.M. Best's ratings are under continual review and subject to change or affirmation. To confirm the current rating visit www.ambest.com.

2

Final ratings vary on the basis of the terms.

Related links

Media Conference

May 15, 2025, 11 AM CEST: YouTube (English language)

Analyst Conference

May 15, 2025, 2:00 PM CEST: YouTube (English language)

Results

The results and related documents can be found in the download center.

Upcoming events

Financial Results 2Q 2025

August 7, 2025

More information can be found in the financial calendar.

About Allianz

The Allianz Group is one of the world's leading insurers and asset managers with around 128 million* private and corporate customers in nearly 70 countries. Allianz customers benefit from a broad range of personal and corporate insurance services, ranging from property, life and health insurance to assistance services to credit insurance and global business insurance. Allianz is one of the world’s largest investors, managing around 768 billion euros** on behalf of its insurance customers. Furthermore, our asset managers PIMCO and Allianz Global Investors manage about 1.9 trillion euros** of third-party assets. Thanks to our systematic integration of ecological and social criteria in our business processes and investment decisions, we are among the leaders in the insurance industry in the Dow Jones Sustainability Index. In 2024, over 156,000 employees achieved total business volume of 179.8 billion euros and an operating profit of 16.0 billion euros for the group.

* As of December 31, 2024. Including non-consolidated entities with Allianz customers.

** As of March 31, 2025.

These assessments are, as always, subject to the disclaimer provided below.

Cautionary note regarding forward-looking statements

This document includes forward-looking statements, such as prospects or expectations, that are based on management's current views and assumptions and subject to known and unknown risks and uncertainties. Actual results, performance figures, or events may differ significantly from those expressed or implied in such forward-looking statements.

Deviations may arise due to changes in factors including, but not limited to, the following: (i) the general economic and competitive situation in the Allianz’s core business and core markets, (ii) the performance of financial markets (in particular market volatility, liquidity, and credit events), (iii) adverse publicity, regulatory actions or litigation with respect to the Allianz Group, other well-known companies and the financial services industry generally, (iv) the frequency and severity of insured loss events, including those resulting from natural catastrophes, and the development of loss expenses, (v) mortality and morbidity levels and trends, (vi) persistency levels, (vii) the extent of credit defaults, (viii) interest rate levels, (ix) currency exchange rates, most notably the EUR/USD exchange rate, (x) changes in laws and regulations, including tax regulations, (xi) the impact of acquisitions including and related integration issues and reorganization measures, and (xii) the general competitive conditions that, in each individual case, apply at a local, regional, national, and/or global level. Many of these changes can be exacerbated by terrorist activities.

No duty to update

Allianz assumes no obligation to update any information or forward-looking statement contained herein, save for any information we are required to disclose by law.

Other

The figures regarding the net assets, financial position and results of operations have been prepared in conformity with International Financial Reporting Standards. This Quarterly Earnings Release is not an Interim Financial Report within the meaning of International Accounting Standard (IAS) 34. This is a translation of the German Quarterly Earnings Release of the Allianz Group. In case of any divergences, the German original is binding.

Privacy Note

Allianz SE is committed to protecting your personal data. Find out more in our privacy statement.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250514121549/en/

Permalink

https://www.aetoswire.com/en/news/1505202546625

Contacts

Media contacts

Frank Stoffel Tel. +49 89 3800 18124 e-mail: frank.stoffel@allianz.com

Ann-Kristin Manno Tel. +49 89 3800 18805 e-mail: ann-kristin.manno@allianz.com

Johanna Oltmann Tel. +49 89 3800 13346 e-mail: johanna.oltmann@allianz.com

Fabrizio Tolotti Tel. +49 89 3800 14819 e-mail: fabrizio.tolotti@allianz.com

Investor Relations contacts

Andrew Ritchie Tel. +49 89 3800 3963 e-mail: andrew.ritchie@allianz.com

Reinhard Lahusen Tel. +49 89 3800 17224 e-mail: reinhard.lahusen@allianz.com

Christian Lamprecht Tel. +49 89 3800 3892 e-mail: christian.lamprecht@allianz.com

Tobias Rupp Tel. +49 89 3800 7151 e-mail: tobias.rupp@allianz.com

 

Africa’s Leading Fintech - Moniepoint - Ranked by the Financial Times as One of Africa’s Fastest Growing Companies, for the Third Consecutive Year

 World’s leading financial publication reiterates Moniepoint’s rapid growth and impact

(BUSINESS WIRE) -- Moniepoint Inc. (“the Company” or “Moniepoint”), announces it has been ranked by the Financial Times as one of Africa’s fastest-growing companies for the third consecutive year, reinforcing its rapid growth as one of the continent's leading financial institutions for Africans, everywhere.

The recognition highlights Moniepoint’s continued ability to achieve strong, scalable growth. In a market where few companies successfully balance size with agility, Moniepoint distinguishes itself by maintaining operational efficiency while accelerating its expansion across the continent.

The world’s leading financial publication confirmed Moniepoint’s accolade in its annual “Africa’s Fastest Growing Companies” survey, released on 14 May, 2025.

The survey was compiled by Statista, a leading research company renowned for its insight into African companies’ actual performance, in a rigorous screening process. Companies were ranked on 2020-2023 data for their (i) absolute growth rate of revenues and (ii) compound annual growth rate (CAGR).

Moniepoint’s growth rates ranked it ahead of hundreds of leading companies from diverse industries such as technology, telecoms, financial services, and healthcare. This achievement is amplified by Moniepoint’s considerable revenue for 2023 (US$264.51 million), unmatched by peers in the ranking’s top 25.

Moniepoint is one of Africa’s leading business payments and personal banking servicing platforms, processing 1 billion+ transactions monthly, with total monthly payments volume of over US$22 billion, serving ten million businesses and individuals across Nigeria.

The accolade for actual performance highlights Moniepoint’s continued success as Africa’s leading fintech. It follows investor endorsement in October’s US$110 million Series C fundraise - and subsequent investment from global digital payments leader, Visa.

Tosin Eniolorunda, Group CEO of Moniepoint Inc., said:

“We are delighted to achieve the very highest of rankings, for the third consecutive year, in the world’s leading financial publication – the Financial Times. We like to let statistics speak for themselves and accolades do not come much higher. Maintaining such rapid growth is only possible due to the hard work of the entire Moniepoint team – and I thank them all for their continued dedication.

“We are very excited about 2025. We continue to innovate and develop new products to support financial inclusion and drive financial happiness - both in Africa and for consumers in the global diaspora.”

The ranking follows last month’s launch by Moniepoint of its first product (MonieWorld) that serves clients outside Africa. Designed to meet the underserved needs of the UK’s African diaspora, MonieWorld is a remittance and digital financial services solution allowing UK customers to send money to Nigeria seamlessly.

Notes to Editors

About Moniepoint

Moniepoint Inc. is Africa’s all-in-one financial ecosystem, helping 10 million businesses and individuals access seamless payments, banking, credit, and business management tools since 2019. As Nigeria’s largest merchant acquirer, it powers most of the country’s Point of Sale (POS) transactions. Through its subsidiaries, Moniepoint Inc. processes $22 billion monthly for its customers while operating profitably.

For more information, please visit https://moniepoint.com/

MonieWorld is a trading name of Moniepoint GB, which is a distributor of PayrNet Limited, a company registered in England and Wales with company number 09883437. PayrNet Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 (FCA reference 900594) for the issuing of electronic money and payment services. Moniepoint GB Limited, Reg No. 5500471, Registered Office: 22 Upper Ground, Floor 8, London SE1 9PD.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250513760905/en/

Permalink

https://www.aetoswire.com/en/news/1505202546634

Contacts

Further information

Ben Rothschild

moniepoint@thoburns.com

+44 7564 584 439

Boomi Acquires Thru, Inc., Strengthening Secure Managed File Transfer (MFT) and Advancing Context-Aware Integration

 CONSHOHOCKEN, Pa. - Thursday, 15. May 2025 AETOSWire 

Acquisition enhances Boomi’s MFT capabilities, unifying API, application, and file-based data movement within a single platform

(BUSINESS WIRE) -- Boomi™, the leader in AI-driven automation, today announced a definitive agreement to acquire Thru, Inc., a provider of enterprise-grade Managed File Transfer solutions and trusted Boomi partner. The acquisition marks a strategic expansion of Boomi’s file-based integration capabilities, all within a single, cloud-native platform that seamlessly manages data movement across APIs, applications, and files.

“As organizations increasingly manage a hybrid mix of API-based and file-based integrations, Thru, Inc.’s proven MFT technology ensures secure, scalable, and compliant file exchange across distributed business ecosystems,” said Greg Wolfe, Chief Commercial Officer at Boomi. “The addition of these capabilities further strengthens Boomi’s ability to deliver dynamic, context-aware integration across diverse data types and systems, especially for those use cases with strict compliance requirements such as SOC 2, and others.”

Boomi and Thru, Inc. have long partnered to deliver MFT solutions to joint enterprise customers in industries like financial services, healthcare, and manufacturing — where file transfer is a mission-critical part of business operations. The acquisition will streamline customer experiences by embedding Thru, Inc.’s functionality directly into the Boomi Enterprise Platform, enabling the integrated management of APIs, applications, and files from a single, intelligent interface.

Boomi’s acquisition of Thru, Inc. represents the latest in Boomi’s continued efforts to modernize the Boomi Enterprise Platform, enhance its automation capabilities, and add increased value to customers. Thru, Inc.'s secure, scalable, and enterprise-grade managed file transfer solution will now form a foundational pillar of Boomi’s secure data exchange strategy, enhancing Boomi’s ability to support customers with end-to-end, secure file transfer at scale. As global enterprises look to modernize legacy MFT tools, the combined strengths of Boomi and Thru, Inc. will offer unmatched flexibility, automation, and security — all within Boomi’s unified platform.

By offering native MFT technology Boomi empowers enterprises with:

Secure and compliant file exchanges - by encrypting data in transit and at rest, scanning for threats, and meeting global compliance standards such as SOC 2 within a zero trust architecture.

Efficient file transfer operations - with an elastic cloud platform capable of high-volume, many-to-many exchanges without additional infrastructure or bottlenecks.

Full operational visibility and control - with centralized monitoring, real-time alerts, and detailed audit trails across all file movement.

The transaction remains subject to customary closing conditions and is currently expected to close by the end of June 2025.

Additional Resources

Learn more about the Boomi Enterprise Platform

Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube

About Boomi

Boomi, the leader in AI-driven automation, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With over 23,000 customers globally and a network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.

Forward-Looking Statement

This press release contains forward-looking statements, including expectations regarding Boomi’s acquisition of Thru, Inc., product integration, and customer outcomes. These statements are based on current assumptions and are subject to risks and uncertainties, such as potential delays in closing, integration challenges, and market factors. Actual results may differ materially. Boomi undertakes no obligation to update forward-looking statements, except as required by law.

© 2025 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250515314260/en/

Permalink

https://www.aetoswire.com/en/news/1505202546647

Contacts

Media Contact:

Kristen Walker

Global Corporate Communications

kristenwalker@boomi.com

+1-415-613-8320

Ras Al Khaimah’s strong economic and investment environment validated by Fitch affirmation of ‘A+’ credit rating, with Stable Outlook

 Ras Al Khaimah, United Arab Emirates - Thursday, 15. May 2025 AETOSWire Print 

The positive rating reflects the Emirate’s strong long-term growth prospects and ongoing economic diversification

 

Ras Al Khaimah’s strategic approach to sustainable, cross-sector growth and strong economic and investment environment has been validated by international credit rating agency Fitch, which reaffirmed the rating at ‘A+’ with a stable outlook.

Ras Al Khaimah Government welcomed the announcement as an endorsement of the Emirate’s resilient and expanding economy, sound fiscal management and the clear vision and unwavering commitment of its leadership to sustainable, long-term development and growth.

The Emirate’s landmark tourism projects, including a major integrated resort, luxury hotels and world-class leisure facilities, combined with a surge in real estate revenue, are creating opportunities for investors, driving further investment and strengthening the Emirate’s economic resilience, according to Fitch.

A Ras Al Khaimah Government spokesperson said: “Ras Al Khaimah’s consistent A+ credit rating is owing to its disciplined economic strategy, ambitious investment agenda and long-term commitment to building a sustainable and diversified economy. The Emirate has experienced significant growth over several years to become an attractive global investment and tourism hub, as well as a leading destination to live, work and explore.”

In March, Ras Al Khaimah successfully issued a 10-year USD1 billion sukuk, while keeping total public-sector debt at just 11% of GDP – one of the lowest levels among Fitch-rated sovereigns. This is expected to fall to 9% by 2026.

Fitch estimated that Ras Al Khaimah achieved real GDP growth of 6.7% in 2024, an increase from 3.6% the previous year. RAK Government anticipates this strong momentum to continue, with average growth projected at 6.1% into 2026. This growth is driven by key strategic initiatives, notably the development of the landmark $5.2 billion Wynn Al Marjan Island integrated resort. Set to open in 2027, the resort is poised to drive further economic expansion.

Fitch also highlighted Ras Al Khaimah’s high GDP per capita, strong governance, political stability and effective rule of law – key factors that contribute to the Emirate’s attractive investment environment. The rating affirmation stands as an endorsement of the Emirate’s solid public finances, robust growth trajectory and its status as a dynamic and secure global hub for business and investment.

Permalink

https://www.aetoswire.com/en/news/1505202546652

Contacts

Media inquiries:

Steven McCombe

media@rakmediaoffice.ae

DDC Announces Record 2024 Growth and Strategic Bitcoin Reserve Initiative in Shareholder Letter by Founder & CEO Norma Chu>

(BUSINESS WIRE)--DDC Enterprise Ltd. (NYSEAM: DDC), today released its 2024 full year results alongside a Shareholder Letter from Founder, Chairwoman, and CEO Norma Chu, underscoring the company’s positive financial performance and unveiling a pioneering Bitcoin accumulation strategy poised to redefine long-term value creation. To Our Valued Shareholders, 2024 was a year of transformative growth and strategic milestones for DDC. I am thrilled to share that we not only met our financial forecasts but exceeded expectations, delivering strong performance across key metrics while laying the groundwork for an even more exciting future. As we enter 2025, our momentum is accelerating, driven by disciplined execution and a bold new chapter in our corporate strategy. 2024 Financial & Operational Highlights Revenue Growth: USD 37.4 million, a 33% year-over-year increase, propelled by the strategic acquisition of U.S. brands and sustained resilience in our core China operations. Margin Expansion: Gross profit margin improved to 28.4%, up from 25.0% in 2023, reflecting stringent supply chain optimization and cost discipline. Path to Profitability: Adjusted EBITDA w...(BUSINESS WIRE)--DDC Enterprise Ltd. (NYSEAM: DDC), today released its 2024 full year results alongside a Shareholder Letter from Founder, Chairwoman, and CEO Norma Chu, underscoring the company’s positive financial performance and unveiling a pioneering Bitcoin accumulation strategy poised to redefine long-term value creation. To Our Valued Shareholders, 2024 was a year of transformative growth and strategic milestones for DDC. I am thrilled to share that we not only met our financial forecasts but exceeded expectations, delivering strong performance across key metrics while laying the groundwork for an even more exciting future. As we enter 2025, our momentum is accelerating, driven by disciplined execution and a bold new chapter in our corporate strategy. 2024 Financial & Operational Highlights Revenue Growth: USD 37.4 million, a 33% year-over-year increase, propelled by the strategic acquisition of U.S. brands and sustained resilience in our core China operations. Margin Expansion: Gross profit margin improved to 28.4%, up from 25.0% in 2023, reflecting stringent supply chain optimization and cost discipline. Path to Profitability: Adjusted EBITDA w...{}